Fig. 4: Highly efficient EBV lytic reactivation in a panel of EBV-positive cancer cells treated with mTZ3-LNPs. | Nature Communications

Fig. 4: Highly efficient EBV lytic reactivation in a panel of EBV-positive cancer cells treated with mTZ3-LNPs.

From: Synthetic BZLF1-targeted transcriptional activator for efficient lytic induction therapy against EBV-associated epithelial cancers

Fig. 4: Highly efficient EBV lytic reactivation in a panel of EBV-positive cancer cells treated with mTZ3-LNPs.

Representative flow cytometry plots show the high efficiency of mTZ3-LNP treatment (48 h) for inducing Zta expression in a panel of EBV-positive tumor cell lines, including (a) NPC (C666-1, NPC76c, C17, NPC43 and NPC-M81), (b) EBVaGC (SNU719, YCCLE1 and AGS-EBV) and (c) Burkitt lymphoma (P3HR1 and Akata-EBV). SNU719 and C666-1 cells treated with NaB were included as a reference of chemically induced lytic reactivation (n = 3 experimental replicates). d The percentages of Zta-positive cells in the NPC, EBVaGC and BL cell lines treated with mTZ3-LNP for 48 h are shown (n = 3 experimental replicates). Data are presented as mean ± SD. e The expression of Zta, its downstream lytic proteins (Rta, BGLF4, and EA-D), and cleaved caspase 3 in YCCEL1, NPC31M81, and C17 cells treated with mTZ3-LNPs were detected by western blotting (n = 3 experimental replicates). Source data are provided as a Source Data file.

Back to article page